NEW YORK, February 15, 2017 /PRNewswire/ --
IDEA Pharma, the leading Path to Market Design practice in pharma/ biotech, is delighted to announce the appointment of Geoff Birkett as Vice President, US Client Development.
With over 30 years of strategic and operational experience in pharma, Geoff brings to IDEA a huge depth of knowledge across launch and in line growth brands, as well as early development products. He also brings a disruptive creative energy that has been key to his success in the industry.
Geoff launched many successful, market leading brands as a senior leader with Lilly, Lundbeck and AstraZeneca, where he held Executive/ President roles in UK/ US/ Germany/ S Africa and Global businesses. He was responsible for one of AZ's biggest ever blockbusters, Seroquel. He has worked as a senior leader in Biotech in recent years, specializing in CNS/ Pain/ Addiction.
"I'm excited to join IDEA Pharma at this time. IDEA have a proven track record of designing the best path to market strategies. It's not cookie cutter, it's clever, based on superior insight. Mike has assembled a great team - I look forward to working with them to take IDEA to the next level."
"Pharma is exploding with possibility, and the need to disrupt traditional management consultancy has never been greater," added Mike Rea, CEO. "I am so excited that our approach - senior talent who have deep hands-on experience, working directly with our clients - is attracting superstars like Geoff. Wanting to make a meaningful difference is a deep part of our ethos, and I know Geoff will look to improve on that success, making sure meaningful medicines continue to reach patients."
About IDEA Pharma:
Through knowledge, insight and uncommon creativity, we unlock the potential of every molecule, inspiring and empowering the pharma industry to deliver medicines that make a difference. We work with clients early in the lifecycle at proof of concept, crafting a compelling product story and building a world-class strategy that helps every molecule reach its potential. It's what we do best. And there's nobody that does it quite like us.
Past Accomplishments Include:
Path to Market Design for 7 of the top 10 (projected) oncology products by 2020 // Positioned 3 of 11 products Reuters called 2015 Blockbusters, including the Top 2 // Path to Market Design for 5 NMEs that were FDA approved in 2015
For further information, please contact:
Manager, Marketing, Brand & Communications
SOURCE IDEA Pharma